Key result
Two weeks of oral estrogen replacement therapy significantly reduced platelet activation markers CD62P (from 7.00% to 3.05%) and PAC-1 (from 41.75% to 20.86%) in healthy postmenopausal women (P<0.001).
Why the study?
Does short-term oral estrogen replacement therapy reduce platelet activation markers in healthy postmenopausal women?
Does short-term oral estrogen replacement therapy reduce platelet activation markers in healthy postmenopausal women?
Short-term estrogen replacement therapy significantly reduces platelet activation markers in healthy postmenopausal women, suggesting a potential mechanism for cardiovascular protection.
Short-term oral estrogen was associated with reduced platelet activation; hypothesis-generating for cardiovascular protection, needs randomized confirmation.
OBJECTIVES: In healthy postmenopausal women (PMW) increased platelet activation has been associated with adverse cardiovascular events. There is much debate about the relationship between platelet function and serum estradiol level in PMW. This study assessed the effect of short-term oral estrogen replacement therapy (ERT) on platelet activation markers (CD62P and PAC-1) and its correlation with age and body mass index (BMI) among healthy PMW. METHODS: A prospective intervention study was conducted at Hospital University Sains Malaysia, involving 48 healthy PMW who were evaluated for platelet activation marker levels as determined by flow cytometry, before and after two weeks of oral ERT with 0.625 mg of conjugated equine estrogen once daily. The pre- and post-ERT platelets activation markers difference was analysed by paired t-test. RESULTS: The pre-ERT, mean ± SD percentage levels of CD62P and PAC-1 were significantly reduced from 7.00 ± 5.91 and 41.75 ± 26.85 to 3.05 ± 2.47 and 20.86 ± 19.02, respectively, after two weeks of ERT (P value < 0.001). The correlation of platelet activation markers was significant with estradiol but not with age and BMI. CONCLUSION: Short-term ERT leads to reduction in platelet activity, which might contribute to protection against cardiovascular diseases in healthy PMW.
No takes yet. Share an insight, caveat, or question.
Sheikh et al. (2011) studied healthy postmenopausal women (n=48). oral estrogen replacement therapy (ERT) vs. baseline (pre-ERT) was evaluated on platelet activation markers (CD62P and PAC-1) (p=< 0.001). Two weeks of oral estrogen replacement therapy significantly reduced platelet activation markers CD62P (from 7.00% to 3.05%) and PAC-1 (from 41.75% to 20.86%) in healthy postmenopausal women (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: